Ferdinando D’Amico | Medicine and Health Sciences | Best Researcher Award

Dr Ferdinando D’Amico, IRCCS San Raffaele Hospital, Italy

Dr. Ferdinando D’Amico is a distinguished gastroenterologist at IRCCS San Raffaele Hospital in Milan, Italy, with expertise in gastroenterology and endoscopy. 🎓 He completed his residency in Gastroenterology/Digestive Diseases and earned his PhD at Hunimed University, focusing on histology in inflammatory bowel diseases. His academic journey includes a degree in Medicine and Surgery from “Cattolica del Sacro Cuore” University, where he researched intestinal permeability and atherosclerosis. 🏥 His training included internships in gastroenterology and cardiology at “Agostino Gemelli” Hospital in Rome. Dr. D’Amico is proficient in English and French, and skilled in digital communication. 🌍🔬

Publication profile

Scopus

Education 

🎓 From 2003 to 2008, attended Classical High School, graduating with highest honours. From 2009 to 2015, pursued a Degree in Medicine and Surgery at “Cattolica del Sacro Cuore” University, Rome, also graduating with highest honours. 🏆 The dissertation, titled “Alterations in Intestinal Permeability and Inflammation: A Novel Potential Mechanism of Atherosclerosis,” was supervised by Professor Filippo Crea. 📜 Currently registered with the Ordine Provinciale dei Medici Chirurghi e degli Odontoiatri di Caserta, registration number 7593. 🩺

Experience

From November 1, 2016, to November 2, 2020, [Name] completed their residency in Gastroenterology/Digestive System Diseases at Hunimed University in Pieve Emanuele, Italy, graduating with highest honors. They then pursued a Ph.D. at the same institution, focusing on “The Role of Histology in Inflammatory Bowel Diseases,” under the guidance of Prof. Silvio Danese. From January 1, 2021, to February 9, 2024, they worked as a Gastroenterologist at the IRCCS San Raffaele Hospital in Milan, Italy, in the Gastroenterology and Endoscopy Unit, also directed by Prof. Silvio Danese. 🏥📚🩺

Research focus

Based on the provided publications, the research focus appears to be on inflammatory bowel diseases (IBD), specifically Crohn’s disease and ulcerative colitis. The studies address various aspects such as comparing treatments (e.g., tofacitinib vs. ustekinumab), assessing remission through non-invasive methods, and evaluating regulatory guidance for JAK inhibitors. The research also explores the use of biologics and other therapies in managing IBD, including switching between different treatment forms. This indicates a strong emphasis on optimizing treatment strategies and improving patient outcomes in IBD. 🌟📚💊

Publication top notes

Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study

Ultrasound remission after biologic induction and long-term endoscopic remission in Crohn’s disease: a prospective cohort study

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study

The role of filgotinib in ulcerative colitis and Crohn’s disease

A new national survey of centers for cognitive disorders and dementias in Italy

An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study

Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn’s disease

MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations

Advancing transmural remission as a treatment target in Crohn’s disease: The future of tight-control strategy?

Noninvasive Assessment of Postoperative Disease Recurrence in Crohn’s Disease: A Multicenter, Prospective Cohort Study on Behalf of the Italian Group for Inflammatory Bowel Disease